AstraZeneca holds talks with Bristol Myers Squibb – Business News
UK drugmaker AstraZeneca has been exploring a deal to mix with US rival Bristol Myers Squibb, the Financial Times reported on Sunday, citing people accustomed to the matter.
The deal may create one of the world’s greatest pharmaceutical teams with a mixed worth of almost $400 billion.
Astra Zeneca has been speaking with Bristol Myers Squibb about a doable mixture, the Financial Times reported. Bloomberg by way of Getty Images
The corporations have held talks on a potential tie-up in latest months, the report stated, including that a deal may materialize quickly, however may be delayed or disintegrate.
Reuters couldn’t instantly confirm the report. AstraZeneca declined to remark, whereas Bristol Myers didn’t instantly reply to a Reuters request for remark exterior common business hours.
Last yr, AstraZeneca unveiled plans for a direct US itemizing, aiming to capitalize on stronger valuations within the US market whereas remaining listed in London.
The company’s share price has more than quadrupled during Pascal Soriot’s 14-year tenure as CEO, hovering above the broader FTSE 100 index and principal British rival GSK.
A mixture of AstraZeneca and Bristol Myers Squibb can be valued at $400 billion, the report stated. dpa/image alliance by way of Getty Images
The Discovery Centre R&D facility at AstraZeneca’s headquarters in Cambridge, England. Bloomberg by way of Getty Images
Second-quarter outcomes final week confirmed sturdy demand for most cancers and uncommon illness medication continues to drive growth. Cancer remedies accounted for about $25 billion in 2025 gross sales, almost half of the full, adopted by cardiovascular, renal and metabolism remedies price about $12 billion.
The report of the potential deal comes about a dozen years after AstraZeneca fended off a takeover attempt by bigger US rival Pfizer.
